

Disclosures All relevant financial conflicts have b	Koetting	
Ocular Therapeutix Glaukos Horizon Quidel Eyevance/Santen Ivantis Orasis Claris Bio Aldeyra Dompe	RVL Oyster Point Allergan Visus Thea Bruder Glaukos B & L Twenty/Twenty	Myze Azura Scope Iveric Bio















DRSS highly imperfect measure

No UWF fundus photos • Detects 50% more H/MAs than ETDRS photos • 12% change in DRSS No FA No UWF FA • Detects 3-5x more MAs than UWF photos No OCT No OCT-a

9









8/6/23













Interactive Polling Question Is referral to a retina specialist warranted? a. Yes





27

<complex-block>

unteractive Polling Question referrat to a retina specialist warranted? b. No c. lam unsure



8/6/23







8/6/23









8/6/23

Omega 3 EPA/DHA and Dry AMD

Multi-center, prospective cohort study examining risk factors for cardiovascular disease Plasma levels of Omega 3's measured (not just dietary intake questionnaire)	Association of plasma w-3 fatty acids with early age- related macular degeneration in the Multi-Ethnic Study of Athenoscienosis (MUSSA) Age Equations and a study and a study and a study of the study and the study and a study and a study and a study of the study Allower + separt Macon study for an anti-Multi-Multi-Allower
 Fundus photographs assessed for AMD using standard grading protocol. Association between higher plasma DHA and DHA + EPA levels and reduced risk for early AMD 40-50% Inwer risk of early AMD 	Abstract Parameters for execution between using 1 junctions and May with PDEAL Based and PDEAL and PDEAL Abstractions and PDEAL and PDEAL PDEAL Abstractions PDEAL and Mark Abstractions Theory PDEAL PDEAL PDEAL PDEAL PDEAL PDEAL PDEAL PDEAL PD
Higher levels of EPA alone were not associated with lower AMD risk controls findings	People. There was a produced an advanced technical produced technical products of the technical model and constraints (PMIC 2011; FLE advanced and constraints) (PMIC 2014; FLE advanced advanc



37









<section-header><text><list-item><list-item>



43















52

8/6/23

Healthy

GA























8/6/23



Author Disclosures and Acknowledgments^a

- Nathan Steinle has the following financial interests or relationships to disclose: trian steinle has the following mancial interests or relationships to disclose: – Consultant: Abdve Inc., Alimera, Allergan, Apelia, Bausch and Lomb, Biogen, Genertech, Novartis, Ocular Therapeutx, Opthea, Oyster Point Pharma, Regeneron, Regenzbio, Vertex Surgical, Zaiss Independent research: Cenertech, Novartis, Regeneron, Regenxbio, Zeiss, Ocular Therapeutx, Opthea – Speaker bureau: Alimera, Apellis, Bausch and Lomb, Biogen, Evolve Medical, Genertech, Novartis, Regeneron, Vindico Medical – Stock and stock options: Vortex Surgery

GALE: 36-Month, Open-Label Extension Study Efficacy analysis: Change in GA tesion area based on 6-month GALE data 3-3-month Conturous spectacoplan treatment compared with sham? - Pegcetacoplan was compared with OAKS and DERIY | e projected sham (6 month GALE) - Peccente linear shoe analysis with - Genomine peccaceptian treatment for sham crossover group GALE (n=782) CAKS, C "Rigect AND, ag v identifien: NCT03525013, NCT0352500, NCT04770545, respectively ulating the average of the mean rate of change of each-c-month period n, ECM, everyother month; GA, geographic skophy, IOI, intradocula shamtreatment. nflammation; IOM, is-

	Number of patients				
	PM	PEOM	SM	SEOM	Overall
OAKS and DERBY ITT population	419	420	206	211	1258
Completed QAKS and DERBY study through Month 24	291	330	154	165	940
	PM to PM	PEOM to PEOM	SM to PM	SEOM to PEOM	Overall
Enrolled in GALE	250	269	129	144	792
Included in modified full analysis set	241	267	129	143	780
Excluded from modified full analysis set No injection received in GALE Enrolled from study other than CAKS or DERBY	0 9	1	8	1 0	2 10

68









	Ph	и	PEOMb		
	24 months	30 months	24 months	30 months	
Study eye, safety set, ^c %	12.2%	16.6%	6.7%	8.6%	
Events per 100 patient-years	7.5	7.2	3.9	3.6	
Fellow eye,* %	4.2%	5.2%	4.1%	4.6%	
Events per 100 patient-years	2.5	2.1	2.4	1.9	
*Fellow eye analysis includes patients at risk for new-onset eAMD.					

















<section-header><section-header><section-header><section-header><text><section-header><text><text><text><text><text><text><text><text><text><text><text><text>



83



87

When to refer nAMD 86

Updates in Treatments for nAMD

b (Vabysmo, Genentech) latest FDA-approved anti-VEGF agent that also inhibits angiopoietin-2 (Ang-2) plays an important role in vascular stability and permeability. The Ang/Tie2 pathway has received significant investigation due to its role in inflammation, and neovascularization.

and newstocularization. High-dood sillowcapt, which is 6 m patients of the currently available 2 mg (Eyles, Ragemenn), has already been shown in Phase 3 clinical that to extend a large proportion of patients to 12-week and 16-week readiment intervals. Selective tyropies themas inhibitions are valid wrown in the oncology field and a nore two-ling investigated for the treatment of VGC-dhem diseases. • These inhibitions wich intracelularly to stop downatineam effects of both VEGF and platele-derived growth factor. Grant etnary is perhaps one of the most exciting Nature directions for substanting disease of anti-VGC with several trabs starsky in the perhaps.

Faricimab

 First in class bi specific monoclonal antibody Dual inhibition of VEGF-A and Angiopoietin-2
Helps with vascular stability and permeability



Life Adaptation changes

- Small changes can make a big impact
- Best corrected MRX
- Possible low vision devices
- Refer out for low vision tra
- Ilsing our phones as a device

89



<section-header><section-header><text><text>

Retinal OCT and Neurological Pathology

Any insult to CNS can potentially result in retina and optic nerve degeneration

Any insult to the neuro-ophthalmological structures can result in the anterograde degeneration of the CNS Analysis of optic nerve and retinal layers can help in diagnosis and management of neurologic disease like multiple sclerosis, neuro-myelitis optica, Alzheimer's disease, and Parkinson's disease

Alzheimer's and AMD

- Meta-analysis of 8 studies, 8,223,581 participants with macular degeneration Significantly associated with demontia, especially in dry AMD pts vs wet Patients with AMD vs no AMD had 12X risk of demontia developing
- 121X risk of AD
 10X ris

Parkinsons and Macula

Shi et al showed a reduction in central macular thickness and macular volume, thinner inner retinal layers correlated with lower motor score PD patients

Possibly suggest depleted dopaminergic cells are not able to communicate with cone receptors in fovea= thinning
 Impairment on the ON Integrity as well as microstructural alterations throughout the visual pathway in the brait have been reported in PD

94

Taive see reperted in FU
Study Lee 2019
Looking at macula and ON simultaneously using OCT
Looking at macula and ON simultaneously using OCT
Found parafoxeal inner refinal layer thinning in drug naïve PD patients
Thimning more prominently in the inner inferior and temporal sectors
ON and refinal changes more likely in those pt with some autonomic, sleep,
fatigue and gat symptomes

93



